Supernus Pharmaceuticals, Inc. (SUPN)
40.70
-1.37
(-3.26%)
USD |
NASDAQ |
Oct 23, 16:00
40.68
-0.02
(-0.06%)
After-Hours: 20:00
Supernus Pharmaceuticals Enterprise Value : 2.035B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 2.035B |
| October 22, 2026 | 2.115B |
| October 21, 2026 | 2.065B |
| October 20, 2026 | 2.066B |
| October 19, 2026 | 1.985B |
| October 16, 2026 | 1.871B |
| October 15, 2026 | 1.970B |
| October 14, 2026 | 2.005B |
| October 13, 2026 | 2.112B |
| October 12, 2026 | 2.158B |
| October 09, 2026 | 2.150B |
| October 08, 2026 | 2.119B |
| October 07, 2026 | 2.172B |
| October 06, 2026 | 2.159B |
| October 05, 2026 | 2.155B |
| October 02, 2026 | 2.133B |
| October 01, 2026 | 2.121B |
| September 30, 2026 | 2.171B |
| September 29, 2026 | 2.226B |
| September 28, 2026 | 2.262B |
| September 25, 2026 | 2.149B |
| September 24, 2026 | 2.186B |
| September 23, 2026 | 2.192B |
| September 22, 2026 | 2.213B |
| September 21, 2026 | 2.156B |
| Date | Value |
|---|---|
| September 18, 2026 | 2.111B |
| September 17, 2026 | 2.165B |
| September 16, 2026 | 2.075B |
| September 15, 2026 | 2.069B |
| September 14, 2026 | 2.081B |
| September 11, 2026 | 2.090B |
| September 10, 2026 | 2.093B |
| September 09, 2026 | 2.115B |
| September 08, 2026 | 2.136B |
| September 04, 2026 | 2.200B |
| September 03, 2026 | 2.226B |
| September 02, 2026 | 2.229B |
| September 01, 2026 | 2.212B |
| August 31, 2026 | 2.240B |
| August 28, 2026 | 2.212B |
| August 27, 2026 | 2.238B |
| August 26, 2026 | 2.279B |
| August 25, 2026 | 2.306B |
| August 24, 2026 | 2.292B |
| August 21, 2026 | 2.335B |
| August 20, 2026 | 2.428B |
| August 19, 2026 | 2.491B |
| August 18, 2026 | 2.520B |
| August 17, 2026 | 2.476B |
| August 14, 2026 | 2.476B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Indivior Pharmaceuticals, Inc. | 4.354B |
| Prestige Consumer Healthcare, Inc. | 4.243B |
| Amphastar Pharmaceuticals, Inc. | 1.465B |
| Bristol Myers Squibb Co. | 159.59B |
| Liquidia Corp. | 3.699B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -58.37M |
| Revenue (Quarterly) | 219.06M |
| Total Expenses (Quarterly) | 277.43M |
| EPS Diluted (Quarterly) | -1.005 |
| Gross Profit Margin (Quarterly) | 72.88% |
| Profit Margin (Quarterly) | -26.65% |
| Earnings Yield | -4.70% |
| Normalized Earnings Yield | -2.736 |